A novel study demonstrates that using nanoparticles to deliver osteoarthritis drugs to the knee joint could help increase the retention of the drug in the knee cavity, and therefore reduce the frequency of injections patients must receive. This research was presented Oct. 23 - 27 at the 2011 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in Washington, D.C.

Osteoarthritis affects 30 million Americans and is the most common joint disorder. It is projected to affect more than 20 percent of the U.S. population by 2025. Aging, obesity and joint injury can lead to osteoarthritis, which is characterized by progressive erosion of articular cartilage (cartilage that covers the bones). The disease can occur in all joints, most often the knees, hips, hands and spine, and currently there are no pharmacological treatments that halt the disease progression. For large joints, a drug could be injected into the joint to help limit potential side effects, like pain. A significant challenge in treating osteoarthritis this way is the short duration the medicine stays in the affected joint after injection.

Lead researcher Michael Morgen, Ph.D., and his colleagues from Bend Research and Pfizer propose to address this challenge with injectable nanoparticles that help retain osteoarthritis drugs in the knee joint. Test results show that 70 percent of the drug nanoparticles remain in the knee cavity after one week. In contrast, for most current formulations, the drug disperses within one to two days.

In this new process, positively charged nanoparticles carrying a drug attach to the negatively charged, naturally occurring molecules in the knee to form a gel. This gel acts as a depot that slows drug escape from the knee cavity.

"Current delivery methods do not maintain the drug in the knee for very long, which limits the effectiveness of therapeutic agents," said Dr. Morgen. "We hope that this type of sustained release technology, when used with current or new osteoarthritis drugs, will allow patients to be effectively treated with drug injections every three months instead of once a week."

  • Additional
  • References
  • Citations

A novel study demonstrates that using nanoparticles to deliver osteoarthritis drugs to the knee joint could help increase the retention of the drug in the knee cavity, and therefore reduce the frequency of injections patients must receive. This research was presented Oct. 23 - 27 at the 2011 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in Washington, D.C.

Osteoarthritis affects 30 million Americans and is the most common joint disorder. It is projected to affect more than 20 percent of the U.S. population by 2025. Aging, obesity and joint injury can lead to osteoarthritis, which is characterized by progressive erosion of articular cartilage (cartilage that covers the bones). The disease can occur in all joints, most often the knees, hips, hands and spine, and currently there are no pharmacological treatments that halt the disease progression. For large joints, a drug could be injected into the joint to help limit potential side effects, like pain. A significant challenge in treating osteoarthritis this way is the short duration the medicine stays in the affected joint after injection.

Lead researcher Michael Morgen, Ph.D., and his colleagues from Bend Research and Pfizer propose to address this challenge with injectable nanoparticles that help retain osteoarthritis drugs in the knee joint. Test results show that 70 percent of the drug nanoparticles remain in the knee cavity after one week. In contrast, for most current formulations, the drug disperses within one to two days.

In this new process, positively charged nanoparticles carrying a drug attach to the negatively charged, naturally occurring molecules in the knee to form a gel. This gel acts as a depot that slows drug escape from the knee cavity.

"Current delivery methods do not maintain the drug in the knee for very long, which limits the effectiveness of therapeutic agents," said Dr. Morgen. "We hope that this type of sustained release technology, when used with current or new osteoarthritis drugs, will allow patients to be effectively treated with drug injections every three months instead of once a week."

  • Additional
  • References
  • Citations
The painting that has touched me the most features a sad little girl and is called A Letter From My Mother. Now we're very close.My sister also shares my love for folk art. I saw a painting he did of a fishing scene but I chose not to buy it. It's of a swamp house on a bayou and has a Louisiana feel to it. I don't particularly care for his art. Maybe it's because I spent a lot of time with my grandmother and her house was full of them. It is done in vibrant colors and also depicts the buildings in the market like an ice cream parlor and the Hotel Van Nuys. It's called Alligator Fisher and I'm thinking about getting because it reminds me of my cajun heritage, most of my family is from Louisiana.I have loved folk art paintings since I was a child. I have a friend who collects these and I found one of a woman reclining in a hammock. One of my favorites that she had was done by John Roeder. I'll find someone to give it to.One.....

In this new process, positively charged nanoparticles carrying a drug attach to the negatively charged, naturally occurring molecules in the knee to form a gel. For large joints, a drug could be injected into the joint to help limit potential side effects, like pain. Test results show that 70 percent of the drug nanoparticles remain in the knee cavity after one week. In contrast, for most current formulations, the drug disperses within one to two days."Current delivery methods do not maintain the drug in the knee cavity, and therefore reduce the frequency of injections patients must receive. "We hope that this type of sustained release technology, when used with current or new osteoarthritis drugs, will allow patients to be effectively treated with drug injections every three months instead of once a week. 23 - 27 at the 2011 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in Washington, D.Osteoarthritis affects 30 million Americans and is the most common joint disorder.D. A significant challenge in treating osteoarthritis this way is the short duration the medicine stays in the affected joint after injection. It is projected to affect more than 20 percent of the U.S. This research was presented Oct.S. Test results show that 70 percent of the drug nanoparticles remain in the knee cavity after one week. In contrast, for most current formulations, the drug disperses within one to two days."Current delivery methods do not maintain the drug in the knee cavity, and therefore reduce the frequency of injections patients must receive. "We hope that this type of sustained release technology, when used with current or new osteoarthritis drugs, will allow patients to be effectively treated with drug injections every three months instead of once a week. 23 - 27 at the 2011 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition She favors animal prints, and I found one that depicts leopards and gave it to her for her birthday. I don't know whose smile is bigger, the one in the painting or the one on my face every time I look at it. I personally don't have any of these in my collection, since I like to collect pieces that I can relate to. Still, they are a joy to behold. I spent a lot of time playing in my tree house, that the trees in the picture appealed to me so much.I have loved folk art paintings since I was a child. I don't particularly care for his art. She looked so relaxed, that I could imagine what it felt like to lie there myself. It was painted in 1988 by Reverend Howard Finster and is done in enamel.One of the most famous American artists is Thomas Chambers. One of my favorites that she had was done by John Roeder.My sister also shares my love for folk art. It is done in vibrant colors and also depicts the buildings in the market like an ice cream parlor and the Hotel Van Nuys. I saw a painting he did of a fishing scene but I chose not to buy it.There is a subcategory of folk art paintings that depict the world of black Americans. When she died, she left me the painting and it hangs in a place of honor over my fireplace mantle.One of my favorite paintings was done in 1962 by Bill Dodge. I'll find someone to give it to. I have a friend who collects these and I found one of a woman reclining in a hammock. It's pretty funny to me that when we were growing up, she'd cry because she wasn't allowed to play football

rthritis association athritis association arhritis association artritis association arthitis association arthrtis association arthriis association arthrits association arthriti association arthritis ssociation arthritis asociation arthritis asociation arthritis assciation arthritis assoiation arthritis assocation arthritis assocition arthritis associaion arthritis associaton arthritis associatin arthritis associatio srthritis association aethritis association atthritis association arrhritis association aryhritis association artgritis association artjritis association artheitis association arthtitis association arthrutis association arthrotis association arthriris association arthriyis association arthritus association arthritos association arthritia association arthritid association arthritis sssociation arthritis aasociation arthritis adsociation arthritis asaociation arthritis asdociation arthritis assiciation arthritis asspciation arthritis assoxiation arthritis assoviation arthritis assocuation arthritis assocoation arthritis associstion arthritis associarion arthritis associayion arthritis associatuon arthritis associatoon arthritis associatiin arthritis associatipn rathritis association atrhritis association arhtritis association artrhitis association arthirtis association arthrtiis association arthriits association arthritsi association arthriti sassociation arthritis sasociation arthritis asosciation arthritis asscoiation arthritis assoication arthritis assocaition arthritis associtaion arthritis associaiton arthritis associatoin arthritis associatino arthritis associatio aarthritis association arrthritis association artthritis association arthhritis association arthrritis association arthriitis association arthrittis association arthritiis association arthritiss association arthritis aassociation arthritis asssociation arthritis asssociation arthritis assoociation arthritis assocciation arthritis associiation arthritis associaation arthritis associattion arthritis associatiion arthritis associatioon arthritis associationn
A novel study demonstrates that using nanoparticles to deliver osteoarthritis drugs to the knee joint could help increase the retention of the drug in the knee cavity, and therefore reduce the frequency of injections patients must receive. This research was presented Oct. 23 - 27 at the 2011 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in Washington, D.C.

Osteoarthritis affects 30 million Americans and is the most common joint disorder. It is projected to affect more than 20 percent of the U.S. population by 2025. Aging, obesity and joint injury can lead to osteoarthritis, which is characterized by progressive erosion of articular cartilage (cartilage that covers the bones). The disease can occur in all joints, most often the knees, hips, hands and spine, and currently there are no pharmacological treatments that halt the disease progression. For large joints, a drug could be injected into the joint to help limit potential side effects, like pain. A significant challenge in treating osteoarthritis this way is the short duration the medicine stays in the affected joint after injection.

Lead researcher Michael Morgen, Ph.D., and his colleagues from Bend Research and Pfizer propose to address this challenge with injectable nanoparticles that help retain osteoarthritis drugs in the knee joint. Test results show that 70 percent of the drug nanoparticles remain in the knee cavity after one week. In contrast, for most current formulations, the drug disperses within one to two days.

In this new process, positively charged nanoparticles carrying a drug attach to the negatively charged, naturally occurring molecules in the knee to form a gel. This gel acts as a depot that slows drug escape from the knee cavity.

"Current delivery methods do not maintain the drug in the knee for very long, which limits the effectiveness of therapeutic agents," said Dr. Morgen. "We hope that this type of sustained release technology, when used with current or new osteoarthritis drugs, will allow patients to be effectively treated with drug injections every three months instead of once a week."

  • Additional
  • References
  • Citations

A novel study demonstrates that using nanoparticles to deliver osteoarthritis drugs to the knee joint could help increase the retention of the drug in the knee cavity, and therefore reduce the frequency of injections patients must receive. This research was presented Oct. 23 - 27 at the 2011 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in Washington, D.C.

Osteoarthritis affects 30 million Americans and is the most common joint disorder. It is projected to affect more than 20 percent of the U.S. population by 2025. Aging, obesity and joint injury can lead to osteoarthritis, which is characterized by progressive erosion of articular cartilage (cartilage that covers the bones). The disease can occur in all joints, most often the knees, hips, hands and spine, and currently there are no pharmacological treatments that halt the disease progression. For large joints, a drug could be injected into the joint to help limit potential side effects, like pain. A significant challenge in treating osteoarthritis this way is the short duration the medicine stays in the affected joint after injection.

Lead researcher Michael Morgen, Ph.D., and his colleagues from Bend Research and Pfizer propose to address this challenge with injectable nanoparticles that help retain osteoarthritis drugs in the knee joint. Test results show that 70 percent of the drug nanoparticles remain in the knee cavity after one week. In contrast, for most current formulations, the drug disperses within one to two days.

In this new process, positively charged nanoparticles carrying a drug attach to the negatively charged, naturally occurring molecules in the knee to form a gel. This gel acts as a depot that slows drug escape from the knee cavity.

"Current delivery methods do not maintain the drug in the knee for very long, which limits the effectiveness of therapeutic agents," said Dr. Morgen. "We hope that this type of sustained release technology, when used with current or new osteoarthritis drugs, will allow patients to be effectively treated with drug injections every three months instead of once a week."

  • Additional
  • References
  • Citations